List of Excipients in Branded Drug DYANAVEL XR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NextWave Pharmaceuticals Inc	DYANAVEL XR	amphetamine	24478-102	ANHYDROUS CITRIC ACID	2029-03-29
NextWave Pharmaceuticals Inc	DYANAVEL XR	amphetamine	24478-102	GLYCERIN	2029-03-29
NextWave Pharmaceuticals Inc	DYANAVEL XR	amphetamine	24478-102	METHYLPARABEN	2029-03-29
NextWave Pharmaceuticals Inc	DYANAVEL XR	amphetamine	24478-102	MODIFIED CORN STARCH	2029-03-29
NextWave Pharmaceuticals Inc	DYANAVEL XR	amphetamine	24478-102	POLYSORBATE 80	2029-03-29

DYANAVEL XR Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

DYANAVEL XR is a once-daily, extended-release amphetamine oral suspension developed by Tris Pharma for attention-deficit/hyperactivity disorder (ADHD). Its commercial differentiation depends on the formulation platform as much as the active ingredient. The product uses a liquid dosage form to address pediatric swallowing, dose titration, and administration flexibility, while excipients support drug-release control, physical stability, preservation, taste, and dose uniformity.

The strongest commercial opportunities are in functional excipients and delivery systems: ion-exchange or microparticle release technologies, suspension stabilizers, taste-masking systems, low-viscosity vehicles, dosing devices, and reformulations that improve storage, palatability, or preservative burden. Generic competition is technically more difficult than for an immediate-release tablet because an applicant must reproduce a complex suspension and demonstrate extended-release equivalence.

What is DYANAVEL XR and how does its formulation work?

DYANAVEL XR is an extended-release oral suspension containing mixed amphetamine salts. The product is indicated for ADHD in patients aged six years and older. The marketed strength is 2.5 mg amphetamine base equivalent per mL, administered once daily in the morning. The dose can be measured and titrated in liquid form. [1]

The formulation addresses several pediatric-use problems:

• Difficulty swallowing tablets or capsules.
• Need for incremental dose adjustment.
• Preference for liquid administration.
• Requirement for once-daily coverage.
• Need for a formulation that remains physically uniform during use.

DYANAVEL XR is a controlled substance classified by the FDA as Schedule II. Its commercial development therefore requires controls over manufacturing, distribution, inventory, serialization where applicable, and diversion risk. [1]

What active ingredients are used?

The product contains four amphetamine salts:

1. Amphetamine sulfate.
2. Amphetamine aspartate monohydrate.
3. Dextroamphetamine sulfate.
4. Dextroamphetamine saccharate.

The label expresses strength as amphetamine base equivalent rather than as the total weight of the salt mixture. This approach is common for mixed-amphetamine products and complicates direct comparison with competing products that use different salt combinations or express strengths differently. [1]

What excipients are used in DYANAVEL XR?

The FDA prescribing information identifies the inactive ingredients as citric acid, glycerin, methylparaben, potassium sorbate, sodium citrate, sucralose, xanthan gum, and purified water. [1]

Excipient	Primary formulation role	Commercial relevance
Xanthan gum	Suspension viscosity and particle-settling control	Controls redispersibility, dose uniformity, mouthfeel, and pourability
Glycerin	Vehicle, humectant, viscosity modifier, and mouthfeel agent	Influences sweetness perception, viscosity, and palatability
Sucralose	High-intensity sweetener	Masks amphetamine-associated bitterness
Citric acid	Acidulant and pH adjustment	Supports taste, preservative performance, and chemical stability
Sodium citrate	Buffer component	Controls pH and supports stability
Methylparaben	Antimicrobial preservative	Protects a multidose aqueous product during in-use storage
Potassium sorbate	Antimicrobial preservative	Provides complementary preservation in the aqueous vehicle
Purified water	Continuous liquid phase	Enables oral suspension delivery

The excipients are not interchangeable from a regulatory perspective. A change in xanthan gum grade, preservative concentration, sweetener, pH, particle size, or viscosity can alter sedimentation, redispersion, dose delivery, release kinetics, taste, and stability.

How does the excipient system support extended release?

The commercial value of DYANAVEL XR lies in a multipart formulation architecture rather than in a simple aqueous amphetamine solution. Tris Pharma has patented extended-release liquid compositions involving drug-containing particles and release-controlling materials. The relevant intellectual-property strategy includes particle engineering, coating, suspension behavior, and oral liquid delivery. [4]

In this type of system, excipients can perform several functions simultaneously:

• Immobilize or complex the active pharmaceutical ingredient.
• Control water penetration into drug-containing particles.
• Slow diffusion or dissolution after administration.
• Maintain particles in a uniform suspension.
• Preserve dose accuracy throughout the bottle’s in-use period.
• Reduce bitter taste before swallowing.
• Permit a commercially acceptable viscosity.

The key development challenge is balancing release control against suspension quality. Increasing polymer or coating strength can slow release but may increase particle density, settling, or incomplete redispersion. Increasing xanthan gum can reduce sedimentation but may produce a thick, difficult-to-pour liquid and an unfavorable mouthfeel.

What formulation patents protect DYANAVEL XR?

The core patent strategy is directed toward extended-release liquid amphetamine compositions and their particle-based delivery mechanisms rather than only the chemical identity of amphetamine.

A publicly identified Tris Pharma patent associated with extended-release liquid pharmaceutical compositions is U.S. Patent No. 9,192,644. The patent relates to liquid formulations containing an active pharmaceutical ingredient in a release-controlled particulate system. [4] The commercial scope of any patent depends on the issued claims, terminal disclaimers, continuity filings, prosecution history, and Orange Book listing status.

Relevant protection categories include:

Protection category	Potential subject matter	Generic impact
Composition of matter	Amphetamine salt mixture	Limited because amphetamine salts are established compounds
Extended-release particles	Drug-resin, coated, or polymer-controlled particles	High technical relevance
Oral suspension	Vehicle, stabilizer, pH, preservation, and particle system	Relevant to same-formulation ANDA strategies
Manufacturing process	Particle loading, coating, blending, and suspension manufacture	Can create process-based barriers
Method of use	Once-daily treatment of ADHD	Potential litigation exposure if listed
Dosing system	Calibrated oral syringe or measurement method	Usually secondary protection

The strength of the estate is therefore concentrated in formulation and manufacturing claims. Those claims can be commercially meaningful even when active-ingredient patents are old or unavailable.

What is the Orange Book status of DYANAVEL XR?

DYANAVEL XR is approved under FDA NDA 208147. The FDA Orange Book is the controlling source for listed patents, exclusivity, dosage-form information, and any paragraph IV-related certification data. [2,3]

The product’s principal regulatory protection came from FDA approval of a new extended-release amphetamine oral suspension rather than from a novel active ingredient. The applicable exclusivity period for a new drug approval is generally five years, subject to the statutory framework and any eligible pediatric extension. Pediatric exclusivity can add six months to qualifying listed exclusivity or patent terms. [2]

Orange Book analysis should distinguish four separate issues:

1. NDA approval and marketing status.
2. Listed patents and their expiration dates.
3. Regulatory exclusivity.
4. Litigation or settlement activity following an ANDA paragraph IV certification.

An Orange Book patent listing does not itself establish infringement. It identifies patents that may be asserted against an ANDA applicant. Patent enforceability, claim construction, validity, and infringement remain litigation questions.

When does DYANAVEL XR lose exclusivity?

DYANAVEL XR’s regulatory exclusivity is distinct from its formulation-patent protection. The five-year new chemical or new drug exclusivity period begins from the relevant approval date and can be affected by statutory exceptions. Pediatric exclusivity may extend applicable protections by six months if awarded. [2]

Patent expiration depends on the specific issued patent, patent term adjustment, patent term extension, terminal disclaimer, and any later continuation or divisional patent. The earliest date at which a generic can launch may therefore differ from the expiration date of the principal formulation patent.

Protection type	Commercial effect
Five-year FDA exclusivity	Restricts certain ANDA filings during the statutory period
Pediatric exclusivity	May add six months to eligible protections
Formulation patent	Can delay or increase the cost of generic entry
Method-of-use patent	May permit a skinny-label strategy if other claims are absent
Manufacturing patent	Can force a non-infringing process or alternative formulation
Litigation settlement	Can establish a negotiated launch date before patent expiry

A precise launch date must be calculated from the live Orange Book listing and the governing patent records. [3]

What generic entry risks exist for DYANAVEL XR?

Generic entry presents a higher technical burden than immediate-release amphetamine tablets. An ANDA applicant must address:

• Pharmaceutical equivalence.
• Strength expressed as amphetamine base equivalent.
• Particle-size distribution.
• Suspension uniformity.
• Redispersibility after storage.
• Delivered dose through the labeled oral syringe.
• Extended-release dissolution profile.
• Preservative effectiveness.
• Microbial limits.
• Container-closure compatibility.
• In-use stability.
• Taste and administration characteristics where relevant to the dosage form.

The FDA’s product-specific guidance for complex dosage forms can require comparative performance testing beyond a conventional tablet bioequivalence study. [5]

What paragraph IV challenges are possible?

A paragraph IV challenge could target one or more listed formulation patents. Likely arguments would include:

• Lack of novelty in the use of known suspension polymers.
• Obviousness based on prior extended-release liquid systems.
• Lack of written description or enablement.
• Non-infringement based on different particle architecture.
• Invalidity based on prosecution-history limitations.
• Alternative formulation that avoids claimed excipient or process features.

A generic applicant could also pursue a non-infringing formulation using different release-controlling materials, provided it meets FDA equivalence requirements. That path can be technically difficult because a change in particle technology may produce different pharmacokinetics even when the label strength is identical.

No broad biosimilar pathway applies. DYANAVEL XR is a small-molecule drug, not a biologic. Competition would proceed primarily through an ANDA, a 505(b)(2) application, or, in some cases, a conventional new drug application for a materially different product.

Which excipient opportunities have the greatest commercial value?

Ion-exchange resins and release-controlling particles

Specialty resins and coated microparticles are the highest-value excipient category. Suppliers that can provide consistent loading, narrow particle-size distributions, low extractables, and pharmaceutical-grade documentation can become strategic partners.

The supplier must support:

• Batch-to-batch drug loading.
• Low residual solvents.
• Controlled particle size.
• Reproducible release profiles.
• Compatibility with amphetamine salts.
• Scalable coating or granulation processes.

Suspension polymers

Xanthan gum is effective but can impose viscosity and mouthfeel limitations. Commercial opportunities exist for alternative polymers or polymer blends that provide:

• Faster redispersion.
• Lower sedimentation.
• Lower viscosity at equivalent suspension stability.
• Better syringeability.
• Reduced dependency on vigorous shaking.

Potential candidates include modified cellulose systems, carbomers, polyacrylic acid polymers, and polymer combinations. Each alternative requires assessment of pH sensitivity, electrolyte tolerance, preservative interaction, and impact on release.

Taste-masking systems

Amphetamine products have an inherent taste challenge. Sucralose alone may not provide adequate masking across all patient populations. Opportunities include:

• Ion-exchange taste masking.
• Polymer coatings.
• Flavor systems designed for acidic oral suspensions.
• Reduced aftertaste.
• Lower sweetness intensity.
• Pediatric sensory optimization.

A taste-masking system that also controls release can create stronger intellectual-property differentiation than a flavor-only change.

Preservative-reduced or preservative-free formats

DYANAVEL XR uses a multidose aqueous container, making microbial control necessary. A preservative-free presentation could improve parent and prescriber acceptance but would likely require a different package architecture, such as:

• Unit-dose sachets.
• Single-use cups.
• Metered-dose dispensing.
• Airless or antimicrobial container systems.
• Shorter in-use dating.

This opportunity is commercially attractive but would require new stability, microbial, packaging, and human-factors work.

What commercial opportunities exist beyond the current DYANAVEL XR product?

The most credible opportunities are adjacent products that preserve the liquid, once-daily positioning while reducing formulation or administration friction.

Opportunity	Commercial rationale	Main barrier
Lower-viscosity suspension	Easier pouring and syringe dosing	Sedimentation and dose uniformity
Preservative-free unit dose	Pediatric and caregiver acceptance	Packaging cost and supply-chain complexity
Improved taste-masked version	May improve adherence	New formulation and comparative studies
Smaller-volume high-concentration product	More convenient administration	Dose uniformity and safety risk
Longer in-use stability	Better pharmacy and caregiver handling	Microbial and chemical stability
Ready-to-use oral syringe presentation	Reduces measuring errors	Device qualification and packaging cost
Alternate flavor platform	Supports patient preference	Flavor interaction with pH and preservatives
Abuse-deterrent liquid design	Addresses controlled-substance concerns	Demonstration of meaningful abuse-deterrent performance

A 505(b)(2) product could target a new concentration, device, preservative system, flavor, or dosing presentation. The sponsor would need to determine whether the change requires clinical bridging, human-factors evidence, comparative pharmacokinetics, or new efficacy data.

How does DYANAVEL XR compare with competing ADHD products?

DYANAVEL XR competes in the extended-release stimulant market, but its liquid dosage form differentiates it from tablet, capsule, orally disintegrating tablet, and chewable products.

Product	Active stimulant	Dosage form	Liquid formulation opportunity
DYANAVEL XR	Mixed amphetamine salts	Extended-release oral suspension	Core product
Quillivant XR	Methylphenidate	Extended-release oral suspension	Direct liquid competitor
Adzenys XR-ODT	Amphetamine	Orally disintegrating tablet	No bottle-shaking or suspension opportunity
Vyvanse	Lisdexamfetamine	Capsule and chewable tablet	Prodrug-based differentiation
Mydayis	Mixed amphetamine salts	Extended-release capsule	Longer-duration solid dosage form
Generic mixed amphetamine salts ER	Mixed amphetamine salts	Capsules or tablets	Price-based competition

Quillivant XR is the closest dosage-form comparator because it also uses a once-daily extended-release liquid. The commercial comparison turns on active ingredient, duration, taste, dosing flexibility, insurance coverage, and pharmacy availability. [6]

What manufacturing and IP barriers affect commercial entry?

The main barriers are process reproducibility and formulation equivalence. A competitor must manufacture a suspension that remains homogeneous enough to deliver the labeled dose while preserving the intended release profile.

Critical manufacturing controls include:

• Particle coating thickness.
• Drug loading.
• Particle-size distribution.
• Bulk density.
• Blend uniformity.
• Suspension viscosity.
• pH.
• Preservative concentration.
• Fill-volume accuracy.
• Container-closure integrity.

Process patents can be as important as composition patents. A generic manufacturer may design around a claimed process, but the alternative process must still produce an equivalent product at commercial scale.

The controlled-substance classification creates a second barrier. Manufacturers need DEA registration, quota management, secure storage, reconciliation procedures, and controlled distribution systems. These requirements raise working-capital and operational costs relative to noncontrolled oral liquids.

What is the likely revenue exposure from generic competition?

Revenue exposure depends on payer mix, pediatric prescribing, net price, market share, and the number of generic entrants. Liquid complex generics often face slower entry than conventional tablets because development and manufacturing are more difficult. Once approved, price erosion can still be substantial if several suppliers enter.

The principal commercial scenarios are:

1. No generic before the primary formulation protection expires.
2. One authorized or settlement-based entrant with moderate price erosion.
3. A first ANDA launch followed by rapid multi-generic competition.
4. A non-infringing 505(b)(2) liquid or alternate dosage form.
5. Prescriber migration to competing liquid stimulants or solid formulations.

For the originator, lifecycle-management value is highest in differentiated dosing devices, improved taste, preservative-free packaging, and formulations that reduce administration errors without changing the active ingredient.

Key Takeaways

• DYANAVEL XR’s differentiation is built around a once-daily extended-release amphetamine suspension.
• Xanthan gum, glycerin, pH modifiers, preservatives, and sucralose support suspension stability, preservation, palatability, and dose delivery.
• The highest-value excipient opportunities involve release-controlling particles, specialty resins, low-viscosity suspension systems, and integrated taste masking.
• Generic development is more complex than for immediate-release amphetamine tablets because particle properties, suspension behavior, release kinetics, and dosing-device performance must align.
• DYANAVEL XR has no biosimilar risk because it is a small-molecule drug.
• Potential lifecycle products include preservative-free unit doses, improved taste systems, lower-viscosity vehicles, higher-concentration liquids, and dosing-device improvements.
• FDA Orange Book listings, patent term adjustments, pediatric exclusivity, and paragraph IV litigation determine the practical generic-entry timetable.

FAQs

Can DYANAVEL XR be reformulated without xanthan gum?

Yes. An alternative suspending polymer or polymer blend could be used, but the sponsor would need to demonstrate equivalent physical stability, redispersibility, delivered dose, dissolution, stability, and bioavailability.

Is DYANAVEL XR sugar-free?

The listed sweetener is sucralose, and the FDA label does not identify sucrose as an inactive ingredient. Product labeling and current commercial packaging should control any sugar-related marketing claim. [1]

Could a preservative-free DYANAVEL XR product be approved?

Yes. A preservative-free product would likely require a new container-closure or unit-dose presentation and supporting data for microbial control, in-use stability, package integrity, and dose delivery.

Does a different flavor avoid DYANAVEL XR formulation patents?

Usually not by itself. Flavor changes may avoid narrow claims directed to a specific flavor system, but they generally do not avoid broader claims covering the extended-release particle or suspension architecture.

Is a liquid amphetamine product eligible for an ANDA?

A therapeutically equivalent liquid product could potentially use the ANDA pathway if it meets FDA requirements for pharmaceutical equivalence and bioequivalence. A materially different formulation, concentration, device, or clinical profile may require a 505(b)(2) pathway. [5]

References

1. U.S. Food and Drug Administration. (2024). DYANAVEL XR (amphetamine hydrochloride, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and dextroamphetamine saccharate) extended-release oral suspension prescribing information. Tris Pharma, Inc.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: DYANAVEL XR, NDA 208147. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Tris Pharma, Inc. (2015). Liquid extended-release pharmaceutical composition. U.S. Patent No. 9,192,644. United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development

6. U.S. Food and Drug Administration. (2012). QUILLIVANT XR (methylphenidate hydrochloride) extended-release oral suspension prescribing information. NextWave Pharmaceuticals, Inc.